Inverse agonists - What do they mean for psychiatry?

Area of Science:

• Pharmacology
• Neuroscience
• Drug Discovery

Background:

• Drug nomenclature is crucial for research and treatment.
• Traditionally, CNS receptor ligands are agonists or antagonists.
• Inverse agonists, a newer class, have opposing effects to agonists.

Purpose of the Study:

• To evaluate the evidence for pimavanserin acting as an inverse agonist in the human brain.
• To determine if the FDA's classification of pimavanserin is supported by in vivo data.
• To propose appropriate nomenclature for pimavanserin based on current evidence.

Main Methods:

• Review and discussion of existing in vitro and in vivo data on pimavanserin's mechanism of action.
• Analysis of the pharmacological evidence supporting inverse agonism versus antagonism.
• Consideration of the implications of drug classification on clinical practice and research.

Main Results:

• Current in vitro data suggests pimavanserin may act as an inverse agonist at the 5-HT2A receptor.
• Evidence for pimavanserin's inverse agonist activity in the human brain is currently insufficient.
• The effects of pimavanserin in humans are not definitively proven to be due to inverse agonism.

Conclusions:

• It is premature to classify pimavanserin as an inverse agonist based on current human brain data.
• Pimavanserin should be considered a 5-HT2A antagonist until more robust evidence emerges.
• Accurate drug nomenclature is essential for advancing scientific understanding and patient care.